226 related articles for article (PubMed ID: 32998939)
1. Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis.
Loomans-Kropp HA; Chaloux M; Richmond E; Umar A
Cancer Prev Res (Phila); 2021 Feb; 14(2):195-204. PubMed ID: 32998939
[TBL] [Abstract][Full Text] [Related]
2. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Nguyen DM; Richardson P; El-Serag HB
Gastroenterology; 2010 Jun; 138(7):2260-6. PubMed ID: 20188100
[TBL] [Abstract][Full Text] [Related]
3. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
4. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
Tan MC; El-Serag HB; Yu X; Thrift AP
Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
[TBL] [Abstract][Full Text] [Related]
5. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study.
Nguyen T; Duan Z; Naik AD; Kramer JR; El-Serag HB
Gastroenterology; 2015 Nov; 149(6):1392-8. PubMed ID: 26208896
[TBL] [Abstract][Full Text] [Related]
6. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis.
Liao LM; Vaughan TL; Corley DA; Cook MB; Casson AG; Kamangar F; Abnet CC; Risch HA; Giffen C; Freedman ND; Chow WH; Sadeghi S; Pandeya N; Whiteman DC; Murray LJ; Bernstein L; Gammon MD; Wu AH
Gastroenterology; 2012 Mar; 142(3):442-452.e5; quiz e22-3. PubMed ID: 22108196
[TBL] [Abstract][Full Text] [Related]
8. Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis.
Hu Q; Sun TT; Hong J; Fang JY; Xiong H; Meltzer SJ
PLoS One; 2017; 12(1):e0169691. PubMed ID: 28072858
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
10. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
11. Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study.
Beales IL; Vardi I; Dearman L; Broughton T
Dis Esophagus; 2013; 26(8):838-46. PubMed ID: 22989236
[TBL] [Abstract][Full Text] [Related]
12. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.
Chen Y; Sun C; Wu Y; Chen X; Kailas S; Karadsheh Z; Li G; Guo Z; Yang H; Hu L; Zhou Q
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2681-2691. PubMed ID: 33575855
[TBL] [Abstract][Full Text] [Related]
13. Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study.
Thota PN; Hajifathalian K; Benjamin T; Runkana A; Lopez R; Sanaka MR
J Dig Dis; 2017 Mar; 18(3):143-150. PubMed ID: 28188977
[TBL] [Abstract][Full Text] [Related]
14. Medication usage and the risk of neoplasia in patients with Barrett's esophagus.
Nguyen DM; El-Serag HB; Henderson L; Stein D; Bhattacharyya A; Sampliner RE
Clin Gastroenterol Hepatol; 2009 Dec; 7(12):1299-304. PubMed ID: 19523538
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis.
Yao H; Wang L; Li H; Xu S; Bai Z; Wu Y; Chen H; Goyal H; Qi X
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):79-88. PubMed ID: 34806503
[TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus.
Khalaf N; Nguyen T; Ramsey D; El-Serag HB
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1832-9.e6. PubMed ID: 24793026
[TBL] [Abstract][Full Text] [Related]
17. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ
Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456
[TBL] [Abstract][Full Text] [Related]
18. The Epidemiology of Esophageal Adenocarcinoma.
Coleman HG; Xie SH; Lagergren J
Gastroenterology; 2018 Jan; 154(2):390-405. PubMed ID: 28780073
[TBL] [Abstract][Full Text] [Related]
19. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
Thrift AP; Anderson LA; Murray LJ; Cook MB; Shaheen NJ; Rubenstein JH; El-Serag HB; Vaughan TL; Schneider JL; Whiteman DC; Corley DA
Am J Gastroenterol; 2016 Nov; 111(11):1528-1535. PubMed ID: 27575711
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
Dunbar KB; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
